Journal of Infection
Volume 60, Issue 5 , Pages 331-337 , May 2010

Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009

  • Marcela Campo

      Affiliations

    • Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    • ,
  • Russell E. Lewis

      Affiliations

    • Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    • College of Pharmacy, University of Houston, Houston, TX, USA
    • ,
  • Dimitrios P. Kontoyiannis

      Affiliations

    • Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    • College of Pharmacy, University of Houston, Houston, TX, USA
    • Corresponding Author InformationCorresponding author. Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 402, Houston, TX 77030, USA. Tel.: +1 713 792 6237; fax: +1 713 745 6839.

,Accepted 28 January 2010.

References 

  1. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood. 1997;90:999–1008
  2. Kontoyiannis DP, Bodey GP, Hanna H, Hachem R, Boktour M, Girgaway E, et al. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma. 2004;45:139–141
  3. Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004;38:1237–1242
  4. Torres HA, Raad , Kontoyiannis DP. Infections caused by Fusarium species. J Chemother. 2003;15:28–35
  5. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98:315–319
  6. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis. 2005;40(Suppl. 6):S401–S408
  7. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122–1131
  8. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821
  9. Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment – rethinking our approach to prevention. Clin Infect Dis. 2001;33:1549–1552
  10. Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47:674–683
  11. CLSI . Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved Standard—Second Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2008;CLSI document M38-A2
  12. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48:265–273
  13. Raad I, Tarrand J, Hanna H, Albitar M, Janssen E, Boktour M, et al. Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer. Infect Control Hosp Epidemiol. 2002;23:532–537
  14. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20:695–704
  15. Marom EM, Holmes AM, Bruzzi JF, Truong MT, O'Sullivan PJ, Kontoyiannis DP. Imaging of pulmonary fusariosis in patients with hematologic malignancies. AJR Am J Roentgenol. 2008;190:1605–1609
  16. Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373–379
  17. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Amé S, Fohrer C, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 2008;47:1176–1184
  18. Raad , Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia. 2008;22:496–503
  19. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350–1360
  20. Ben-Ami R, Lewis RE, Raad , Kontoyiannis DP. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis. 2009;48:1033–1041
  21. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad , Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989–2006. Clin Infect Dis. 2006;43:1580–1584
  22. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007). Cancer. 2009;45:4745–4752

PII: S0163-4453(10)00037-X

doi: 10.1016/j.jinf.2010.01.010

Journal of Infection
Volume 60, Issue 5 , Pages 331-337 , May 2010

Article Tools

* Image Usage & Resolution